Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma.
Jonathan S CebonMartin GoreJohn F ThompsonIan D DavisGrant A McArthurEuan T WalpoleBernard Mark SmithersVincenzo CerundoloP Rod DunbarDuncan MacGregorCyril FisherMichael MillwardPaul NathanMichael P N FindlayPeter HerseyThomas R Jeffry EvansChristian Hermann OttensmeierJeremy MarsdenAngus G DalgleishPhilippa CorrieMarples MariaMargaret A BrimbleGeoff WilliamsSintia WinklerHeather M JacksonLiliana Endo-MunozCandani S A TutukaRalph VenhausLloyd J OldDennis HaackEugene MaraskovskyAndreas BehrenWeisan ChenPublished in: Journal for immunotherapy of cancer (2021)
The vaccine was well tolerated, however, despite inducing antigen-specific immunity, it did not affect survival endpoints. Immune escape through the downregulation of NY-ESO-1 and/or HLA class I molecules on tumor may have contributed to relapse.